Navigation Links
Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
Date:4/15/2009

treatment and wound care therapy using cell technology."

Stemedica will work with Dr. Applegate as she advances her proprietary cell treatment for pediatric burns and wound care into a Phase III trial in Switzerland. In turn, Dr. Applegate will assist Stemedica in securing FDA clearance for an IND ("Investigative New Drug") and Phase I clinical trial in the United States for the same applications. Noting why she chose Stemedica, Dr. Applegate said, "Stemedica's commitment to innovative cell product development and its reputation for high quality cell processing is exactly what I was looking for in a partner. I have conducted due diligence on all the best players in this space and find that Stemedica shares my vision to deliver the highest quality care to those who need it the most."

Nikolai Tankovich MD, PhD, Stemedica's President and Chief Medical Officer, stated, "We believe our collaborative work with Dr. Applegate's Phase III clinical trial in Switzerland will be an excellent first step in demonstrating our innovative cell development capabilities along with our manufacturing strengths in the marketplace. Further, we believe the compelling results from Dr. Applegate's Phase I and Phase II clinical trials in Switzerland will be very helpful to Stemedica as we advance our burn and wound care efforts with the FDA here in the United States. Finally, the working agreement with Dr. Applegate comes at an opportune time for Stemedica as we recently announced the opening of our international operations, Stemedica International, in Lausanne, Switzerland which is also where Dr. Applegate is headquartered."

Stemedica anticipates approaching the FDA for an IND to conduct a Phase I clinical trial in the next few months. Dr. Applegate's Phase III clinical trial in Switzerland is scheduled to begin this fall.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. (

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Renowned Stem Cell Researcher Files Study Results With Stemedica
2. CIRM Completes Briefing Visit to Stemedica Cell Technologies
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
5. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
6. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
7. New Generation Biofuels Signs Sales Contract with Catoctin Mountain Growers to Supply up to 370,000 gallons of Renewable Biofuel
8. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
9. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
10. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
11. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
(Date:11/23/2009)...cative new study, a University of Utah scientist a...jor cause of global warming cannot be stabilized ...ilds the equivalent of one new nuclear power plant... be any substantial near-term departure from recen...on rates," says the new paper by Tim Garrett, an a...
(Date:11/23/2009)...unication, computation and more powerful ways to e...antum states as carriers of information is an extr...hown, mathematically, how to gently tease out unwa... the information intact. Their work is reported in...d highlighted with a Viewpoint in Physics ( http...
(Date:11/23/2009)...e-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDLI ...2009astheex-dividenddateforits$200millionspecialdi...transactioncompletedonNovember2,2009.Thedividendwi...ontherecorddate,December1,2009.NASDAQhassettheappr...fcommonstockforpurposesoftheex-dividenddateonNovem...
(Date:11/23/2009)...tCall/--NeogenCorporation(Nasdaq: NEOG )announcedt...sBoardofDirectorsatthecompany,srecentannualmeeting...xperienceinthefood,agriculture,andtradeindustriesa...leconomicsatVirginiaTechUniversity.FromJanuary2006...enegotiatorwiththerankofambassador. ,, "Sinceou...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Richard T. Crowder Joins Neogen's Board of Directors 2
...erMune, Inc.,(Nasdaq: ITMN ) today announced tha...er and President of InterMune, will present at the...San Francisco on January 15, 2009 at 1:00 p.m.,PST...entation, investors and other,interested parties m...une,s,corporate website at http://www.intermune.c...
...do Biosciences, Inc. announced today that David J....er, will be presenting at the 27th Annual J.P. Mor...Wednesday, January 14, 2009, at 11:30am Pacific Ti...n will include a review of the Company,s lead comp... and enterprise-level business initiatives. , , ...
...AND, New Zealand, Jan. 6 MicroDose Technologies, ...hey have entered into a collaboration to investiga...) technology with MicroDose,s next generation elec...of the agreement, MicroDose will fund the developm...latform and incorporating Nexus6,s SmartinhalerLiv...
Other Biology Technology:MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler 2MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler 3
(Date:11/23/2009)...ber 16, 2009 -- A USDOE and USDA study concluded t...nd, and cropland pasture could be converted from c..., such as switchgrass, from which biomass could be...cally viable production of a perennial grass monoc...s are removed annually is expected to require nitr...
(Date:11/23/2009)...uthern California biomedical engineer and cardiolo...l to help clinicians distinguish cardiac emergenci...ms manageable with drugs and lifestyle change. , ...o the arteries feeding the heart, offer an inside ...ood vessels, often revealing deposits of a dangero...
(Date:11/23/2009)...tute of General Medical Sciences (NIGMS), part of ...ing $42.3 million for grants in scientific areas i...veloped the GO grant program to stimulate biomedic...y the American Recovery and Reinvestment Act (Reco...romise to have a significant impact on a field of ...
Breaking Biology News(10 mins):Switchgrass produces biomass efficiently 2Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 1ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 4US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 1US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 3US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 1US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 2US Oncology Inc to Exhibit iKnowMed 28TM 29 at the 2009 ASCO EHR Symposium 3A Harnessing the EHR 3A From Incentives to Sustainability 5225 3
...s release is available in German . , , It has a...zation determines the shape of precious stones, bu...How this comes about, has been known for a long ti...tute of Colloids and Interfaces are now whittling ... explain numerous phenomena. The researchers inves...
...s release is available in German . , , A joint ..., Spain) and the Max Planck Institutes of Biochemi...he non-invasive and nanoscale resolved infrared ma...od, which is based on near-field microscopy, opens...f high-performance materials or for contact-free m...
...UMBUS, Ohio) A new strategy developed in the Neon...nwide Children,s Hospital is helping premature inf...ficulties learn to feed on their own. According to...ournal of Pediatric Gastroenterology and Nutrition...o help 15 out of 20 infants with severe feeding di...
Other Biology News:A crystal clear view of chalk formation 2A crystal clear view of chalk formation 3A crystal clear view of chalk formation 4Tension in the nanoworld 2Crib-side studies help struggling newborns go home without feeding tubes 2Crib-side studies help struggling newborns go home without feeding tubes 3
...your samples with eArray and Agilents custom print... create your own microarray designs that meet your...e and receive delivery of your arrays in weeks, an...ray creation application tool that enables you to ...
...utine trace metal analytical lab that require high...se instrumentation. The 7500ce offers unmatched de...ces found in the environmental industry. It is equ...found in the clinical, foods, petrochemical, metal...
Mouse Anti-Polio component type I Monoclonal Antibody, Unconjugated, Clone 9B4 from AntibodyShop A/S
Mouse Anti-Human Choriongonadotropin (hCG) Monoclonal Antibody, Unconjugated, Clone 5F10 from AntibodyShop A/S
Biology Products: